Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
Dinosaurs brought busy weekend traffic to a halt on Saturday but thankfully avoided causing a tyrannosaurus wreck. Both residents and tourists of Dubai were stunned to see a convoy of ferocious dinosaurs making their way to their new home in IMG Worlds of Adventure, the world’s largest indoor theme park.
Despite being escorted by Dubai police, one dinosaur was reported missing as the caravan roared through the city. A hunt to capture the fugitive dinosaur is on! Anyone spotting it is requested to report their sighting on social media using the hashtag #SpotTheDino.
The dinosaurs are a part of a collection of sixty-nine state-of-the-art animatronic creatures created by leading Japanese company Kokoro, which are now installed at IMG Worlds of Adventure, set to open early next year. IMG Worlds of Adventure is owned by IMG Theme Park L.L.C. and comprises four zones: MARVEL, Lost Valley-Dinosaur Adventure, Cartoon Network and IMG Boulevard. IMG Worlds of Adventure will also feature a 12 screen state-of–the-art Novo cinema with 3 VIP theaters and a giant IMAX screen.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7623051-dinosaurs-roar-through-dubai/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7377451-novo-nordisk-shanghai-diabetes/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Novo Nordisk today announces the launch of ‘Cities Changing Diabetes’, an ambitious new partnership programme to fight the urban diabetes challenge. The ‘Cities Changing Diabetes’ programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow.
“The global diabetes epidemic is an emergency in slow motion,
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
